Introduction: To assess the outcomes from multidisciplinary board meetings (MDM) for patients with breast cancer liver metastases (BCLM) and identify prognostic factors for survival. Results: 61 patients with BCLM were referred to the MDM. Treatment pathways included surgical resection (n=23), radiofrequency ablation (RFA, n=11), or chemotherapy (n=27).
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Introduction
Breast cancer is the most prevalent female cancer. The most recent epidemiological study conducted by the World Health Organisation on cancer identified that there were 1.67 million new diagnoses of breast cancer in 2012 (1) . The global incidence of breast cancer has risen substantially over the past 30 years and continues to rise due to increased pervasiveness of risk factors (1) (2) (3) . The survival of patients with breast cancer has improved over a similar time period. This has been attributed to the development of better systemic therapies and earlier diagnosis (4) (5) (6) . The prevalence of distant metastases in invasive breast cancer can range from 29.0% to 53.2% (2) . The 5-year overall survival (OS) for localised breast cancer is 98.6%, which is prolonged, compared to 24.3% with distant metastases (7) .
The liver is the 3 rd most common site for breast metastases (8, 9) . Approximately 50% of patients with metastatic breast cancer will eventually develop breast cancer liver metastases (BCLM) (10) . Patients with solitary BCLM have a median survival of approximately 25 months with chemotherapy (11, 12) . The 2nd international consensus guidelines for advanced breast cancer (ABC2) outlined that systemic therapy, with chemotherapy and hormone therapy, is the current first line treatment modality in patients with BCLM(13). However, there is a lack of knowledge as to the best treatment modalities in BCLM due to a paucity of randomised data for the use of loco-regional treatments. It is therefore currently recommended that both surgery and radio-frequency ablation (RFA) of liver deposits are carried out in a highly selective patient cohort. The most recent systematic review of resection and ablation identified that these treatments may, however, have the potential to improve survival producing 5-year OS rates between 21-61% and 27-41% respectfully(14).
Resection and ablation are both used with curative intent in the treatment of both colorectal liver metastases (CLM) and neuroendocrine liver metastases. Guidelines for both diseases indicate that hepatic resection is best indicated when it is possible to obtain a clear-margin resection with acceptable residual functioning volume, and controllable extrahepatic M A N U S C R I P T The primary aim of this study is to compare the survival outcomes for patients with BCLM discussed at multidisciplinary board meetings (MDMs). Additionally, this study hoped to identify prognostic factors for OS in patients with BCLM. and OS were calculated from the date of commencement of chemotherapy regimen or surgery, as applicable. DFS was calculated by presence of recurrence by the latest follow-up recorded.
A C C E P T E D ACCEPTED MANUSCRIPT

Materials and Methods
Treatment algorithm
Case-by-case based discussion at the MDM was carried out to reach a consensus with regards to treatment modality. All patients were discussed in a MDM with surgeons and oncologists present. Prior to discussion at the MDM it was established whether patients demonstrated systemic dissemination via staging. If patients had systemic disease they were treated with first line chemotherapy and subsequently evaluated in the MDM to identify if systemic control had been obtained. A treatment algorithm, outlined in figure 1 , was used to aid management decision. Patients with unresectable disease were offered chemotherapy. If these patients had a good or partial response they were restaged for discussion at a future MDM.
Those who had resectable metastases underwent positron emission tomography-computed tomography (PET-CT) to determine the presence of extrahepatic disease. For those with isolated BCLM, they underwent hepatectomy or RFA. Those patients with BCLM and a single bony metastasis were treated using the same algorithm as those with isolated BCLM on a case-by-case consideration. Otherwise, those with extrahepatic disease had chemotherapy.
Liver Resections were performed either via laparoscopic or open techniques. Major resections were defined as those consisting of 3 or more liver segments. Data regarding postoperative morbidity and mortality, R0 resection, and repeat liver resections were collected.
Postoperative morbidity was defined as complications within 90 days of surgery according to the Clavien-Dindo classification (22) .
Follow up
Follow up schedule was dependent on MDM outcome. Those who underwent surgery were followed up within one month post-operatively following MDM discussion with regards to histopathological findings and the resection margins of the tumour. Those who had RFA had a follow up interval CT scan at 6 weeks post-RFA with MDM discussion of the scan the following week and clinic review at 8 weeks. Those who were referred to oncology for systemic chemotherapy were discussed in the MDM after completion of their intended treatment course and assessment of their response to treatment.
Data Analysis:
Continuous variables were analysed using one-way ANOVA and Kruskal-Wallis tests according to whether the data was parametric. Survival data were estimated using the Kaplan-Meier method and were compared using a stratified log-rank test. Univariate analysis was used to identify prognostic factors for OS.
Prognostic factors with a p-value<0.05 were included in a cox regression model. A cox regression model of univariate factors of p<0.1 and p<0.2 was constructed to further investigate importance of prognostic factors. In multivariate analysis, significance was determined by p<0.05. All statistical analysis was carried out using SPSS (v.24.0.0.0, IBM, Armonk, NY, USA).
Results
A total of 80 consecutive patients were treated for breast cancer liver metastases (BCLM) at KCH between 2005 and 2016. KCH is a tertiary care centre and consequently follow-up for a M A N U S C R I P T The clinical and pathological features of BCLM are summarised in Table 2 . The number of liver metastases was fewer in the hepatectomy patients (1.6 ±1.0) compared to RFA (2.6 ±2.7) and chemotherapy (5.5 ± 2.9; p<0.001). Chemotherapy patients (n=17, 63%) had a significantly greater number of BCLM with bilobar distribution than RFA (n=4, 36%) or hepatectomy (n=4, 17%; p=0.002). Concomitant extrahepatic disease was most prevalent in chemotherapy patients (n=17, 63%; p=0.005). A higher proportion of patients who underwent hepatectomy (n=19, 95%) and RFA (n=7, 88%) as their definitive treatment had either a good or partial response to chemotherapy than for those who chemotherapy was the definitive treatment (n=6, 33%; p<0.001). Figure 2 ). This identified that resection(p=0.002) and RFA(p=0.001) were associated with improved OS compared to chemotherapy. 1-, 3-and 5-year OS rates were 100%, 95%
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and 56% for the hepatectomy cohort, 100%, 100% 100% for the RFA cohort and 81%, 51%
and 25% for the chemotherapy group. In comparison of hepatectomy and RFA subgroups neither groups suffered post-operative mortality. Postoperative morbidity was nil in the RFA group. There were 4 incidences(17%) of 90-day morbidity in the hepatectomy group (bile leak and narrowing of the common bile duct n=1; subdural haematoma n=1; seizure activity due to cerebral metastases n=1; not recorded n=1). 
Prognostic Factors
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Discussion
It is currently unclear as to optimum treatment strategy for patients with BCLM due to an absence of randomised data comparing treatment modalities. The results of this study showed that hepatectomy and RFA were associated with 56% and 100% 5-year OS respectively. This compared to 25% overall survival in patients who received chemotherapy. In addition to this there were no peri-operative deaths following hepatectomy or RFA. Moreover, the incidence of morbidity following invasive treatment was 17% in hepatectomy patients and 0% in RFA improved outcomes (29, 30) . This is integral in identifying the most appropriate treatment algorithms for individual centres and indeed regional workforce planning.
Hepatectomy and RFA have only previously been compared to medical treatment in a 2016
case-control study. This found no statistically significant differences between the 5-year OS of patients who underwent hepatectomy or RFA(38%) or had medical therapy(39%)(31).
These differences may be as a result of the difference between responses to chemotherapy in the patients reported in this study. Both hepatectomy(94%) and RFA(86%) had a high proportion of patients who had disease regression as a result of chemotherapy, according to RECIST criteria (21) . Univariate analysis found lack of response to chemotherapy to be a predictive factor for poor prognosis, which might have contributed to the poorer OS outcomes in the chemotherapy group. Combination therapy of chemotherapy and surgery will have allowed for complete clearance of BCLM and simultaneous treatment of micrometastases in those that were responsive. This highlights the potential for the use of medical therapy for downstaging BCLM. Utilising surgery in patients with tumours who are responsive to chemotherapy can also help to prevent significant sequelae associated with long-term chemotherapy treatment, especially in the liver (32) . Medical therapy has previously been shown to improve survival in CLM by downstaging hepatic disease to allow resection (33, 34) .
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However, no studies have examined this effect in BCLM treatment. Future studies analysing the survival benefits of resection following downstaging of BCLM will help in the production of management guidelines. In the downstaging of tumours it is also important to consider at which point it becomes appropriate to introduce locoregional treatments. In order to ensure that resection is conducted in a timely manner tumours should be reassessed frequently for response to medical therapy. It is recommended that if response is not achieved within 6
months then the treatment strategy should be reassessed to optimise quality of life (35) .
Moreover, in analysis of the data presented in this study we note that 18% patients treated with RFA had more than 5 metastases. RFA in patients with greater than 5 metastases has previously been recommended against, however the recent CIRSE guidelines indicate that this should no longer be an absolute contraindication providing complete ablation of all lesions can be completed (36) . Utilisation of this approach in theory will also allow for more patients to be treated with curative intent.
The presence of extrahepatic metastases was found to be predictive of poor survival on multivariate analysis(HR=14.21). Two previous studies have also found extrahepatic disease to worsen prognosis in BCLM (37, 38) . The manifestation of coexisting extrahepatic disease is indicative of more aggressive disease and limits the ability for resection and RFA to provide clearance of metastatic deposits. In CLM, extrahepatic disease no longer precludes a patient from surgery so long as there is good response to chemotherapy and the disease is resectable (33) . CLM however are as a result of haematogenous spread though the portal tract, whilst BCLM indicate further systemic spread and the presence of micro-metastases, possibly contraindication curative resection or RFA. On univariate analysis bone metastases were not found to reduce OS to statistically significant levels(HR=2.37), indicating that isolated bone metastases may not contraindicate surgical resection. Bone metastases in breast cancer may be the result of local invasion from the primary cancer. Prospective trials should be implemented to identify if ablation or resection in combination with adjuvant chemotherapy can be utilised to achieve complete metastatic clearance in this cohort.
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It is important to analyse these results in light of the methodological limitations. As a retrospective cohort study, these results are subject to selection bias. Moreover, some patients
were not included in the present study due to being followed up at their home institution, compounding the selection bias. The sample size of this study was limited and the methodology would have been improved by including a higher number of patients. This study has however analysed RFA and resection as separate therapies. This reduced the sample sizes of the group, however, as genuine clinical equipoise exists between the effectiveness of these treatments in BCLM it is beneficial to examine the differences between these cohorts.
Moreover, the patients included in this study were treated over a short time period. Whilst increasing the time period would have increased the sample size it may have biased the results due to continuing development of improved therapies to treat breast cancer(4-6).
Additionally, these patients were all treated after 2005, indicating that the treatments used are in line with current beliefs on best practice. Finally, in regards to treatment subgroups, it is important to be aware of the differences in clinicopathological characteristics of each patient cohort and that cox regression analysis cannot completely exclude this bias. As highlighted by the recent consensus on the treatment of advanced breast cancer, randomised controlled trials are urgently needed to guide best practice according to these characteristics(13).
Conclusions
Resection of BCLM appears to improve OS in selected patients with BCLM compared to medical therapy alone. However, no differences were distinguished in OS between RFA and resection cohorts. Extrahepatic disease was found to be associated with reduced OS. This indicates that BCLM patients are most likely to benefit from resection or RFA in the absence of macroscopic extrahepatic disease. Nevertheless, randomised controlled trials are required in the future to elicit which patients would most benefit from liver directed therapies. 
